Morgan Stanley Maintains Overweight on Bicara Therapeutics, Lowers Price Target to $30

Benzinga · 6d ago
Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and lowers the price target from $41 to $30.